Skip to main content
David Loeb, MD, Pediatric Hematology & Oncology, Bronx, NY, The Childrens Hospital at Montefiore Medical Center

DavidMarkLoebMD

Pediatric Hematology & Oncology Bronx, NY

Pediatric Sarcoma Oncology, Pediatric Solid Tumor Oncology

Associate Professor of Pediatrics; Chief, Pediatric Hematology, Oncology, and Marrow & Blood Cell Transplantation, Children's Hospital at Montefiore

Dr. Loeb is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Loeb's full profile

Already have an account?

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Pediatric Hematology/Oncology, 1997 - 2000
  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Pediatrics, 1994 - 1997
  • Columbia University Vagelos College of Physicians and Surgeons
    Columbia University Vagelos College of Physicians and SurgeonsClass of 1994

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2017 - 2025
  • MD State Medical License
    MD State Medical License 1997 - 2018
  • American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2012-2014
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
  • America's Top Doctors for Cancer Castle Connolly, 2011-2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) Following Solid Organ (SOT) or Allogeneic Hematop...
    David Loeb, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

  • Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
    Reduced Intensity Haploidentical BMT for High Risk Solid TumorsMarch 5th, 2013

Hospital Affiliations